Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation
Introduction
The mucopolysaccharidosis (MPS) diseases are a group of lysosomal storage disorders caused by a deficiency in one of the lysosomal enzymes that catalyzes the degradation of glycosaminoglycans (GAGs). Lysosomal accumulation of GAGs results in cellular dysfunctions, organ abnormalities, and metabolic defects through mechanisms that are not entirely understood [1], [2], [3], [4]. Currently, there are eleven known lysosomal enzyme deficiencies that lead to seven distinct MPS diseases. MPS I is caused by a deficiency of α-l-iduronidase (EC 3.2.1.76, encoded by the IDUA gene) that leads to the lysosomal accumulation of dermatan sulfate and heparan sulfate. Depending upon the amount of residual α-l-iduronidase activity, the severity of the MPS I phenotype can vary widely. Consequently, MPS I has been categorized as having three distinct phenotypic subtypes: MPS I-Hurler (MPS I-H), the severe form; MPS I-Scheie (MPS I-S), the mild form; and MPS I-Hurler/Scheie (MPS I-HS), an intermediate form. MPS I-H is a progressive disorder with multiple organ and tissue involvement that includes skeletal deformities, hearing loss, corneal clouding, heart failure and mental retardation. Patients usually die within their first decade as a result of obstructive airway disease, respiratory infection, or cardiac complications [2].
Two naturally occurring MPS I-H animal models have previously been characterized. The first was a feline model with a three-nucleotide deletion in the Idua gene that results in the loss of a single amino acid in the α-l-iduronidase protein [5], [6]. A canine model was later identified with a splice site mutation that causes retention of an intron in the Idua mRNA and leads to premature termination of α-l-iduronidase protein synthesis [7], [8], [9]. In addition, two MPS I-H mouse models have been generated using knock-out strategies that disrupt the Idua gene using an insertion cassette [10], [11]. The MPS I-H animal models have phenotypes that are generally consistent with the disease manifestations of MPS I-H patients, including deficiency of α-l-iduronidase activity [11], [12], accumulation of GAGs in most tissues [6], [10], [11], [13], [14], increased urine GAG excretion [11], [15], accumulation of GM2 and GM3 gangliosides in the brain [16], [17], abnormal facial appearance [16], [18], bone deformities [11], [19], neuropathology [20], [21], and cardiac manifestations [22], [23].
These existing animal models have proven to be valuable tools to investigate the pathogenesis of MPS I-H, and to evaluate several therapeutic strategies such as stem cell transplantation [12], enzyme replacement therapy [24], and gene therapy [15], [19]. However, the current animal models are not useful in evaluating the effectiveness of other promising therapeutic approaches. In particular, the lack of MPS I-H mouse models that carry mutations identified in MPS I-H patients limits many prospective investigations since some therapeutic approaches target a specific mutation or mutation type. In order to obtain an MPS I-H animal model that can be used to investigate a wider range of therapeutic approaches, we generated an Idua-W392X knock-in mouse model that carries a nonsense mutation corresponding to the IDUA-W402X mutation, the most common mutation found in MPS I-H patients. Here we report the characterization of the IDUA-W392X mouse. We evaluated the phenotype of Idua-W392X mice at three ages and found that mutant mice developed a quantifiable disease progression. We found evidence of biochemical, metabolic, and morphological abnormalities that correlate closely with the phenotype described for other MPS I-H animal models [10], [11], [14] as well with the human MPS I-H disease [2]. Thus, the Idua-W392X mouse will allow us to evaluate the efficacy of therapeutic approaches that previously have been limited by the availability of a suitable MPS I-H animal model.
Section snippets
Generation of the Idua-W392X knock-in mouse
The Idua-W392X targeting construct was made using a 129/Sv mouse genomic DNA fragment containing Idua exons 3–14 [11]. The W392X mutation (TGG → TAG) was introduced into exon 9 of the Idua gene by site-directed mutagenesis and was verified by sequencing. A viral thymidine kinase negative selectable marker was placed directly upstream of Idua exon 3, and a loxP-flanked neomycin-resistance positive selectable marker was cloned into the BstZ17I restriction site within the intron between exons 8 and
Replacement targeting of the Idua locus in murine ES cells
A replacement-targeting construct was generated using a 129/Sv mouse genomic DNA fragment containing Idua exons 3–14 (Fig. 1A) [11]. The W392X mutation (TGG → TAG), which corresponds to the W402X mutation found in MPS I-H patients, was introduced into exon 9 of the Idua gene. Thymidine kinase and neomycin-resistance genes were introduced into the targeting construct to provide a means of identifying ES cell clones that had undergone homologous recombination. After transfecting 129/Sv ES cells
Discussion
In this study, we report the generation and characterization of an Idua-W392X knock-in mouse model of MPS I-H. The Idua-W392X mutation is analogous to the IDUA-W402X mutation found in MPS I-H patients. We found that this mouse has a phenotype similar to other MPS I-H animal models and to human MPS I-H. The Idua-W392X mutation results in loss of α-l-iduronidase activity, leading to a significant increase in GAG levels in multiple tissues and an increase in urine GAG excretion. Abnormal tissue
Conclusions
The Idua-W392X mouse was found to have biochemical, metabolic, and morphologic defects that are consistent with the MPS I-H disease phenotype. These quantitative phenotypes are highly reproducible and relatively convenient to measure, thus serving as excellent markers to monitor therapeutic effects. Most importantly, the Idua-W392X mouse is suitable for evaluating therapeutic interventions that target premature stop mutations and NMD.
Acknowledgments
This study was supported by NIH Grant R01 NS057412. The authors also acknowledge the assistance of the UAB Transgenic Mouse Facility (NIH P30 CA13148, P30 AR048311, and P30 AR046031) and the UAB Small Animal Phenotyping Laboratory (NIH P30 DK56336, P30 AR046031, P30 NS057098, and P60 DK079626).
References (53)
- et al.
Lysosomal disorders: from storage to cellular damage
Biochim. Biophys. Acta
(2009) - et al.
Identification and characterization of the molecular lesion causing mucopolysaccharidosis type I in cats
Mol. Genet. Metab.
(1999) - et al.
Architecture of the canine IDUA gene and mutation underlying canine mucopolysaccharidosis I
Genomics
(1992) - et al.
Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow
Mol. Genet. Metab.
(2003) - et al.
Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy
Brain Res. Bull.
(2007) - et al.
Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-l-iduronidase gene
Mol. Ther.
(2004) - et al.
Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice
Mol. Ther.
(2005) - et al.
Progression of multiple behavioral deficits with various ages of onset in a murine model of Hurler syndrome
Brain Res.
(2008) - et al.
Long-term memory for aversive training is impaired in Idua(−/−) mice, a genetic model of mucopolysaccharidosis type I
Brain Res.
(2006) - et al.
Cardiac manifestations in the mouse model of mucopolysaccharidosis I
Mol. Genet. Metab.
(2005)
Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I
Biochem. Mol. Med.
A fluorometric assay using 4-methylumbelliferyl alpha-l-iduronide for the estimation of alpha-l-iduronidase activity and the detection of Hurler and Scheie syndromes
Clin. Chim. Acta
Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector
Mol. Ther.
Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method
Methods
Effect of neonatal administration of a retroviral vector expressing alpha-l-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice
Mol. Genet. Metab.
Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation
Mol. Ther.
Lysosomal dysfunction results in altered energy balance
J. Biol. Chem.
Introducing sense into nonsense in treatments of human genetic diseases
Trends Genet.
Stop-codon read-through for patients affected by a lysosomal storage disorder
Trends Mol. Med.
The clinical outcome of Hurler syndrome after stem cell transplantation
Biol. Blood Marrow Transplant.
Pathogenic cascades in lysosomal disease – Why so complex?
J. Inherit. Metab. Dis.
The cell biology of lysosomal storage disorders
Nat. Rev. Mol. Cell Biol.
Alpha-l-iduronidase deficiency in a cat: a model of mucopolysaccharidosis I
Pediatr. Res.
A canine model of human alpha-l-iduronidase deficiency
Proc. Natl. Acad. Sci. USA
Canine alpha-l-iduronidase deficiency. A model of mucopolysaccharidosis I
Am. J. Pathol.
Cited by (46)
Reduction of lysosome abundance and GAG accumulation after odiparcil treatment in MPS I and MPS VI models
2023, Molecular Genetics and Metabolism ReportsPhenotypic characterisation of the Mucopolysaccharidosis Type I (MPSI) Idua-W392X mouse model reveals increased anxiety-related traits in female mice
2023, Molecular Genetics and MetabolismIdentification of a novel fusion Iduronidase with improved activity in the cardiovascular system
2022, Molecular Genetics and Metabolism ReportsLiver-directed gene therapy corrects neurologic disease in a murine model of mucopolysaccharidosis type I-Hurler
2022, Molecular Therapy Methods and Clinical DevelopmentCitation Excerpt :In addition, it has also been found that 4-month-old IDUA knockout mice show significant spatial learning and memory deficits in the Morris water maze, but this difference decreases in 6- to 8-month-old IDUA knockout mice and wild-type mice.24 There are currently no behavioral studies of this MPS I-H mouse model, but abnormal lysosomal storage in the brain of this model was observed as early as 5 weeks of age, became more significant at 10 weeks of age, and was still increasing at a later time point.21 To test spatial learning and memory abilities, we used a modified Barnes maze (DMP dry maze).25